Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the
upcoming poster presentations of new clinical, translational and
preclinical data with duvelisib (IPI-145),
an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta
and PI3K-gamma at the 2015 American Society of Clinical Oncology (ASCO)
Annual Meeting, taking place May 29-June 2 in Chicago, Il. Duvelisib is
the only dual inhibitor of PI3K-delta,gamma in Phase 3 clinical
development and is in registration-focused studies in patients with
indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia
(CLL). Infinity and AbbVie are jointly developing duvelisib in oncology.
Key results to be presented include new Phase 1 safety and efficacy data
in patients with treatment-naïve CLL, preclinical data that further
support evaluating duvelisib in combination with other therapeutic
agents including venetoclax, an investigational inhibitor of the BCL-2
protein, and translational data that support the role of PI3K-delta and
PI3K-gamma in hematologic malignancies and the tumor microenvironment.
The following four presentations of duvelisib at ASCO 2015 will take
place on Sunday, May 31, 2015, from 8:00 a.m. to 11:30 a.m. CDT (9:00
a.m. – 12:30 p.m. ET) in South Hall A at McCormick Place:
Title: Early clinical activity and pharmacodynamic effects of
duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL
(Abstract #7074)
Lead author: Manish R. Patel, MD, Sarah
Cannon Research Institute/Florida Cancer Specialists
Session:
Leukemia, Myelodysplasia, and Transplantation
Title: High throughput in vitro combination sensitivity screen in
hematologic malignancies with the phosphoinositide-3-kinase (PI3K)- δ,γ
inhibitor, duvelisib (Abstract #8559)
Lead author: Kerrie
Faia, MS, Infinity Pharmaceuticals, Inc.
Session: Lymphoma
and Plasma Cell Disorders
Title: Serum chemokines and cytokines in CLL patients treated
with duvelisib, a PI3K- δ,γ inhibitor (Abstract #7072)
Lead
author: Mark Douglas, MS, Infinity Pharmaceuticals, Inc.
Session:
Leukemia, Myelodysplasia, and Transplantation
Title: A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in
combination with obinutuzumab in patients with CLL/SLL previously
treated with a Bruton’s tyrosine kinase inhibitor (BTKi) (Abstract #
TPS7100)
Lead author: James Stewart Blachly, MD, Ohio State
University Medical Center
Session: Leukemia, Myelodysplasia,
and Transplantation
About Duvelisib
Duvelisib is an investigational, oral, dual inhibitor of
phosophoinositide-3-kinase (PI3K)-delta and PI3K-gamma that is being
jointly developed by Infinity Pharmaceuticals, Inc. and AbbVie Inc. in
oncology. The PI3K pathway is known to play a critical role in
regulating the growth and survival of certain types of blood cancers.
Duvelisib is designed to block the growth and survival of tumor cells by
inhibiting PI3K-delta and PI3K-gamma signaling.
Duvelisib is being evaluated in registration-focused studies, including
DYNAMOTM, a Phase 2 study in patients with refractory
indolent non-Hodgkin lymphoma, DYNAMO+R, a Phase 3 study in patients
with previously treated follicular lymphoma, and DUOTM, a
Phase 3 study in patients with relapsed/refractory chronic lymphocytic
leukemia. Duvelisib is also being evaluated in CONTEMPO, a Phase 1b/2
study in treatment-naïve patients with follicular lymphoma and
SYNCHRONY, a Phase 1b study in CLL patients whose disease is refractory
to or has relapsed while receiving a BTK inhibitor.
Duvelisib is an investigational compound and its safety and efficacy
have not been evaluated by the U.S. Food and Drug Administration or any
other health authority.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to
discovering, developing and delivering best-in-class medicines to people
with difficult-to-treat diseases. Infinity combines proven scientific
expertise with a passion for developing novel small molecule drugs that
target emerging disease pathways. For more information on Infinity,
please refer to the company’s website at www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
including those regarding the company’s expectations about the timing
and type of data presentations and the therapeutic potential of
PI3K-delta, gamma inhibition and of duvelisib, alone or in combination
with other agents. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or results
to differ materially from the company’s current expectations, including,
for example, that there is no guarantee that duvelisib will successfully
complete necessary preclinical and clinical development phases, or gain
regulatory approval, that Infinity’s strategic collaboration
with AbbVie will continue, and other risks described in greater detail
under the caption “Risk Factors” included in Infinity’s quarterly report
on Form 10-Q filed with the Securities and Exchange Commission (SEC)
on May 6, 2015, and other filings filed by Infinity with the SEC. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Infinity expressly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Copyright Business Wire 2015